Amgen's research and development facility in San Francisco. (courtesy photo) It was another strong quarter for biotech giant Amgen, as the company beat Wall Street expectations in both revenue and earnings in the third quarter. Announced after the markets closed Nov. 3, Thousand Oaks-based Amgen reported that sales in the third quarter of 2026 increased…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
